FindTrial
Sign In

Impact of P53 and SIRT1 in Type 2 Diabetes

Investigating the Impact of p53 and SIRT1 in the Development of Type 2 DM Through the Treatment of Prediabetic Individuals by Either Nigetella Salivata or Metformin

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03925714
Enrollment
90
Registered
2019-04-24
Start date
2019-04-01
Completion date
2028-12-31
Last updated
2019-04-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

DM

Brief summary

Investigating the impact of p53 and SIRT1 in the development of type 2 DM

Detailed description

Investigating the impact of p53 and SIRT1 in the development of type 2 DM through the treatment of prediabetic individuals by either nigetella salivata or Metformin

Interventions

OTHERlife style

life sryle control only

DRUGMetformin

metformin twice daily

DRUGNigetella salivata

NS twice daily

Sponsors

Sherief Abd-Elsalam
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Prediabetic subjects.

Exclusion criteria

* Confirmed diabetes. * Hepatic or renal impairment.

Design outcomes

Primary

MeasureTime frameDescription
Number of patients with improved insulin resistance6 monthsNumber of patients showing improved insulin resistance

Countries

Egypt

Contacts

Primary ContactSherief Abd-Elsalam, ass. prof.
sheriefabdelsalam@yahoo.com00201147773440

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 23, 2026